Story

Latigo Biotherapeutics Shares Surge Over 14% in Public Market Debut

ENTHMSVIIDZHZH-TWJAKOHI
Aug 7, 20261 min read
Latigo Biotherapeutics Shares Surge Over 14% in Public Market Debut
Text size
Background

Shares of Latigo Biotherapeutics (NASDAQ: LTGO) surged more than 14% in the company's public market debut on Friday. The stock was trading at $20.53 in early market activity, according to a report from Zhitong Finance.

Focus on Non-Opioid Pain Relief

Latigo Biotherapeutics is a clinical-stage company focused on developing non-addictive alternatives to opioid-based painkillers. Its pipeline is aimed at addressing a significant unmet need for effective pain management without the risk of dependency.

The company's lead drug candidate, LTG-001, is an oral medication being developed for the treatment of moderate-to-severe acute pain, including post-operative pain. The goal is to provide a level of pain relief comparable to opioids while avoiding their well-documented addictive properties.

Sample IUX Markets – In-articleAd

Scientific Approach

LTG-001 functions as a selective inhibitor of the Nav1.8 sodium ion channel. This specific mechanism is key to its safety profile.

  • The Nav1.8 channel is primarily expressed in peripheral pain-sensing neurons.
  • By targeting these peripheral neurons, the drug is designed to block pain signals without acting on the central nervous system.
  • This approach is intended to prevent the potential for addiction that is characteristic of opioid medications, which directly affect the brain.

Read next

More on Stocks
Back to latest news

LATEST